The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G).
I. McCaffery
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Y. Tudor
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Deng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
R. Tang
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. Badola
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. L. Kindler
Consultant or Advisory Role - Abbott Laboratories; Amgen; Bristol-Myers Squibb; Clovis Oncology; Merck; Otsuka; Roche
C. S. Fuchs
Consultant or Advisory Role - Alnylam; Amgen; AstraZeneca; Bristol-Myers Squibb; ImClone Systems; Merck; POZEN; Roche
E. Loh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
S. D. Patterson
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
L. Chen
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
J. L. Gansert
Employment or Leadership Position - Amgen
Stock Ownership - Amgen